OPINION Genetics and its potential to improve type 1 diabetes care
INTRODUCTION
Type 1 diabetes (T1D) is a complex autoimmune disorder that arises from the action of multiple genetic and environmental risk factors and can affect up to one in 300 children [1] . T1D arises from the autoimmune destruction of the insulin-producing b cells of the pancreas, resulting in dependence on exogenously administered insulin to maintain glucose homeostasis. On the basis of concordance of T1D in monozygotic (sharing 100% of genes) twin pairs, it has been estimated that the familial (heritable) risk for T1D is nearly 40%, with the remainder due to nongenetic causes [2] . The concordance of T1D in dizygotic (sharing 50% of genes) twin pairs is nearly 8%, similar to that risk in siblings of a person with T1D. The population prevalence of T1D varies by ethnicity, with highest rates in those of Northern European Caucasian ancestry (4/1000), with particularly high rates in Finland. Given the higher rates of T1D in those of white ancestry, there are many families with two or more children with T1D; nonetheless, the prevalence of T1D in those of nonwhite ancestry remains significant [3] .
GENETIC BASIS OF TYPE 1 DIABETES
A conceptual framework of the progression to T1D was provided by George Eisenbarth, with the fundamental assumption that T1D develops based upon a singularly susceptible genetic background [4] . A compelling modification of this process is that there are sets of genes and variants that may play a role at each stage of the clinical course, leading to T1D (Fig. 1) . Genome-wide linkage and genomewide association studies (GWAS) have made great progress in the discovery of loci associated with risk of T1D. The first region of the genome implicated in risk for T1D, and the region with the greatest contribution to risk, includes the human leukocyte antigen (HLA) genes on human chromosome 6p21 [5, 6] . The HLA genes reside in the human major histocompatibility complex (MHC), and the specific genes with variation associated with T1D risk are HLA-A, HLA-B and HLA-C (class I) and HLA-DR, HLA-DQ and HLA-DP (class II). Specific HLA alleles (that define amino acid residues) in each gene are at a higher frequency in those with T1D than 'controls' (susceptibility alleles) or at a much lower frequency than controls (protective alleles). HLA contributes nearly 50% to the total genetic risk of T1D, with other, non-HLA, T1D loci having smaller effects on disease risk relative to HLA but comparable effect sizes to risk loci identified in other common human disorders.
Genes in the major histocompatibility complex (human leukocyte antigen)
The allelic variation in the most strongly associated HLA region genes (HLA-DRB1, HLA-DQA1 and HLA-DQB1) alter specific amino acid residues that affect binding and presentation of foreign peptides (antigens) that underlies the autoimmune disease process. The well established HLA-DQB1 position 57 residue [7] accounted for nearly 15% of the total risk of T1D, with HLA-DRB1 position 13 and HLA-DRB1 position 71 residues accounted for an additional 12% of risk [8
In white populations, these three amino acid residues capture nearly 27% of T1D risk, or nearly 80% of the MHC-associated risk. In other populations, different HLA class I and HLA class II alleles contribute to risk by encoding different amino acid residues [10, 11] . The relationship between genetic variant and amino acid residue with risk prediction is not simple, and the biology underlying the role of HLA and T1D risk remains an active area of research. Nonetheless, the impact of HLA on T1D risk is substantial.
Non-HLA region genes associated with type 1 diabetes Until 10 years ago, few non-HLA candidate genes had been identified (e.g. INS [12] , CTLA4 [13] , PTPN22 [14] , IL2RA [15] ). The T1DGC identified a new locus (UBASH3A) [16] through linkage analysis and subsequently conducted the first robust T1D genome-wide association study (GWAS) [17] . From the GWAS, over 40 loci attained genome-wide significance, 18 of which were novel (Fig. 2) ; however, these loci were large (250 kb) and contained a mean of seven genes (range ¼ 0-28) [18] . A custom genotyping array of nearly196 000 SNPs was then used to interrogate 186 loci that were robustly associated with one or more of 12 autoimmune diseases [19 && ]. Evidence for T1D association in 44 of these regions was identified, 38 that had been discovered previously, four newly found loci (1q32.1, 2q13, 4q32.3, 5p13.2) and two loci (17q21.31 and 21q22.3) implicated in T1D through strong association with other autoimmune diseases.
KEY POINTS
The risk of T1D is roughly one-half genetic and onehalf environmental.
Specific variants/amino acid residues in HLA class II genes (HLA-DR, HLA-DQ, HLA-DP) account for one-half of the genetic risk.
The remainder of the genetic risk is being resolved, with the genetic variants appearing to be enriched in DNA regulatory regions (enhancers) in specific immunerelevant cell types.
A group of genetic variants associated with T1D are also associated with autoantibody expression and timing of their appearance.
Inclusion of T1D-associated genetic variants can improve the prediction of those at risk and should be considered in population screening for T1D. The stage of progression in type 1 diabetes, shown with individuals having a baseline genetic risk (accounting for 50% of total risk, with half of the genetic risk due to HLA gene variation), but with progression to the subsequent stages of disease defined by individual genetic factors (some that could be consistent across all stages, but with differing impact), leading to clinically defined T1D. Adapted from [4] .
A Bayesian approach was used to establish a 99% credible set of SNPs ([19 && ]) for each of the 44 T1D loci, which reduced the size of the loci and the number of potential candidate genes from an average of seven to two per locus. This information can be used for construction of relevant genetic risk scores (GRS) predicting T1D, or for individual characterization of T1D-associated genetic variants with clinical correlates of T1D.
Regulatory variation and cell specificities as contributors to type 1 diabetes risk [20] . Children expressing at least two autoantibodies had nearly70% progression to T1D by the 10 years; in contrast, 15% progressed to T1D with one antibody expressed over the same period. Further, the age of diagnosis of T1D was highly correlated with age of appearance of first autoantibody, emphasizing the impact of early detection and early screening. When data from DAISY were pooled with prospective cohort studies from Finland and Germany (a total of over 13 000 children), the progression to T1D at 10-year follow-up in 585 children with multiple islet autoantibodies was 69.7%, compared with 14.5% in children with a single islet autoantibody and 0.4% in those with no islet autoantibodies [21] . Progression to T1D in the children with multiple islet autoantibodies was faster for those with early (<3 years) expression of islet autoantibodies and for those with HLA DR3/DR4-DQ8 genotype. This pattern has been replicated in many studies, most recently in The Environmental Determinants of Diabetes in the Young (TEDDY). TEDDY followed 8503 children at an increased genetic risk (based upon HLA genotype) with respect to IAA, GAD and IA-2A autoantibodies measured every 3 months until 4 years of age and every 6 months thereafter; if results were positive, the FIGURE 2. Type 1 diabetes loci mapped by studies during a 'genomic era'. The size of the effect (odds ratio) of each locus on T1D risk using genome-wide association studies (GWAS), defined by the most significantly associated SNP and the location of that SNP (either in or near a likely candidate gene). The early era (blue, 1970-2000) is characterized by discovery of genes with large (odds ratio >2) effects that can be found with small sample sizes or in families. The second era (green, 2001-2006) included discovery of genes with smaller effect that required larger sample size (PTPN22, CTLA4) or scans of nonsynonymous SNPs (coding variation, IFIH1). The third era (red, 2007-2008) was the entry into large case-control studies with genome-wide coverage, led by the Wellcome Trust Case-Control Consortium (2000 cases of seven diseases compared with 3000 common controls), in which more loci with small effects were identified. The recent era (yellow, 2009-present) established large consortia (Type 1 Diabetes Genetics Consortium) in which ever larger sample sizes permitted detection of loci with small effects (OR < 1.1) but potentially discovering important biology. Adapted from [18] . autoantibodies were measured every 3 months. The number of autoantibodies, age at first persistently confirmed autoantibodies and HLA genotypes were associated with an increased risk of T1D in those persistently autoantibody positive [22 & ]. Further, in TEDDY, presence of autoantibodies at 3 (0.1%) and 6 (0.2%) months of age were rare. Of the 549 participants with autoantibodies during follow-up, 43.7% only had IAA, 37.7% only had GAD, 13.8% only had IAA and GAD, 1.6% only had IA-2A and 3.1% had other combinations [23] . The incidence of 'IAA only' was early (within the first year of life), while the incidence in the 'GAD only' group increased until the second year and remained relatively constant, with different HLA-DR frequencies. Thus, the autoantibodies that are predictive of conversion to clinical T1D occur at different times in the clinical course and are influenced by genetic factors (certainly HLA, but perhaps other genetic factors).
GENETICS CAN INCREASE PREDICTION OF ISLET AUTOIMMUNITY AND TYPE 1 DIABETES
Multiple studies have shown the critical role of genetic variation in HLA-DR and HLA-DQ genes on expression of islet autoantibodies and progression/ risk to T1D. Given the growing list of non-HLA genes and variants associated with T1D risk, several have been evaluated for association of the non-HLA variants with islet autoimmunity. In the DAISY cohort, single SNPs in 20 non-HLA genes were evaluated for association with islet autoimmunity and T1D risk [24] , based upon the findings of the T1DGC GWAS [17] . The T1D-associated SNPs in UBASH3A and PTPN22 were associated with both islet autoimmunity and T1D risk, while the T1D-associated PTPN2 SNP was associated only with islet autoimmunity, and the INS T1D-associated SNP was associated only with T1D [24] . In a later study, SNPs in an additional seven non-HLA genes (ERBB3, CLEC16A, IL27, CTRB, C14orf64, GSDM, HORMAD2) were evaluated for association with islet autoimmunity and T1D risk, as well as examining their independent predictive value while controlling for the effects of HLA-DR, DQ genotypes [25] . The prediction of T1D and modelling genetic effects was addressed earlier using six HLA SNPs and 48 non-HLA SNPs for in nearly 4000 T1D cases and nearly 4000 controls [26] , demonstrating that the area under the receiver operating characteristic (ROC) curve is 0.738, which increased slightly by the addition of the non-HLA SNPs. In DAISY [25] , the genetic risk prediction model included only HLA class II (HLA DR3/4-DQ8), and risk SNPs in PTPN22 and UBASH3A, yet it significantly improved prediction of T1D for those in the high genetic risk group (45% by age 15 years) compared with those in the low genetic risk group (3% by age 15 years).
In TEDDY, a more comprehensive analysis of the T1D-associated SNPs was performed, with genotyping of 41 non-HLA SNPs from the T1DGC GWAS [17] in 5164 white children [27 && ]. During the median follow-up time of 57 months, 350 children developed at least one persistent islet autoantibody (GAD IA-2A or IAA) and 84 of them progressed to T1D. After adjustment for multiple testing, SNPs in four non-HLA genes were associated with development of islet autoimmunity and T1D: PTPN22, ERBB3, SH2B3 and INS. In the Finnish DIPP study [28] , 39 non-HLA SNPs were assessed for the development of autoantibody positivity and T1D progression in 521 autoantibody-positive and 989 control children. Similar to other studies, SNPs in the PTPN2, INS, PTPN22, IFIH1 and IKZF4/ERBB3 genes were associated with autoantibody positivity and progression to T1D. Although genes in the HLA region remain the most important genetic risk factors for development of islet autoimmunity and progression to overt T1D, other non-HLA genetic factors contribute to the disease process, a first step in understanding the pathogenesis of T1D.
GENETICS AND POPULATION SCREENING FOR TYPE 1 DIABETES
There has been an increasing recognition that the genetic influence on development of autoantibodies relevant to the development of T1D is being clarified, the detection of autoantibodies that reflect initiation and progression of islet autoimmunity is being defined across multiple populations and the staging of progression to T1D is being established [29 & ]. The fundamental question is no longer 'should there be population screening for T1D' but 'how best to conduct the screening'. The Fr1da Model Project Diabetes 2015 [30 && ] is a German effort to screen for multiple islet autoantibodies at 'well child' visits at 3 and 4 years of age (200 000 children). There is a two-step assay with replicate sampling/testing in situations of two positive autoantibodies for determination of family contact and follow-up. This process will permit detection of those individuals who have early evidence of islet autoimmunity.
An unanswered question is whether this screening can be made more targeted by using a GRS to focus on those with a high 'genetic risk'. With the cost of genotyping declining, even a 96 SNP panel can be rapidly deployed for nearly$7/person. The sensitivity and specificity of the GRS has been shown to have an area under the ROC curve approaching 0.9 for T1D; however, with the low prevalence of islet autoimmunity and T1D in the general population (4/1000 in Northern Europeans, lower in those of African or Asian ancestry), the positive and negative predictive values remain poor. Our current concept is that genetics contributes nearly 50% to risk for T1D, with very little known about the nongenetic contribution to risk. As we accumulate the majority of genetic risk variants in multiple populations, the opportunity will come to test genetic screening, followed by autoantibody testing, in the general population. As shown by the DAISY, TEDDY and other studies, the GRS for T1D and islet autoimmunity does improve prediction, and having increased surveillance and monitoring reduces the risk of diabetic ketoacidosis (DKA), reduced hospitalizations and lower HbA1c levels. There is little doubt that application of genetic and immunologic tools can enhance the detection of an at-risk population for islet autoimmunity and T1D.
CONCLUSION
The field of T1D genetics has progressed from HLA genotypes to a few non-MHC genes (INS, CTLA4, PTPN22) to the present situation of more than 40 risk loci with intriguing overlaps with other autoimmune diseases. We have shown evidence that the set of causal variants are enriched in regulatory (noncoding) regions of the genome, likely involved in gene regulation in specific cell types. The mechanism by which the genetic variation alters gene regulation and impacts development of islet autoimmunity and progression to T1D is unknown. Critically, further research will add to our understanding of genetic impact on the natural history of disease as well as identifying new point of intervention and targets of prevention. Even in the absence of this biological understanding, the genetic variation that is associated with islet autoimmunity and progression to T1D can be used to better identify those in the population who are at risk. The combination of genetic risk and autoantibody screening can be used to form a basis for public health detection, better preservation of beta-cell function and improved management of those with T1D.
